Arlene O. Siefker-Radtke, MD, on Comparing Immunotherapy and Antibody-Drug Conjugates for Urothelial Bladder Cancer

Posted: Friday, March 19, 2021

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, talks about how different classes of agents might be used to extend survival, whether sequentially or in combination. She also touches on preventing or mitigating toxicities related to immune checkpoint inhibitors.